Press Releases

NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Terra Property Trust, Inc. (the “Company”) announced yesterday that it has extended the expiration date of its previously announced exchange offer (the “Exchange Offer”) to exchange all validly tendered unsecured 6.00% Senior Notes due June 30, 2026, issued by the Company (the “Existing Notes”) for a combination of (i) new 11.00% Senior Secured Notes due July 1, 2027 to be issued by the Company (the “Exchange Notes”) and (ii) cash. The Exchange Offer is being made pursuant to the Company’s Registration Statement on Form S-4 (File No. 333-295631) (as amended, the “Registration Statement”), which has been filed with the Securities and Exchange Commission (the “SEC”).

BRATISLAVA, Slovakia and MONTREAL, June 11, 2026 (GLOBE NEWSWIRE) -- ESET Research’s tracking of OceanLotus activities from 2024–2026 has revealed a shift in operational focus as the Vietnam-aligned group adopted a more selective approach to external operations while placing increasing emphasis on domestic espionage. ESET researchers identified two distinct campaigns involving the SPECTRALVIPER backdoor: a supply-chain attack targeting stock market investors in Vietnam, and a prolonged espionage operation against a Vietnamese infrastructure and transport construction company.

Ebene Cybercity, Mauritius, June 11, 2026 (GLOBE NEWSWIRE) -- IUX has published a new article titled “5 ETF Risks to Understand During Volatile Markets,” examining several factors that may influence ETF performance during periods of heightened market uncertainty.

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.

ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced an upcoming presentation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.